"Bringing Innovation and Precision to Psychiatry: A Symposium with Boehringer Ingelheim" will take place on Tuesday, July 2, from 12:45 to 3 p.m., at 100 College St., room 1116.
Over the last decade, Boehringer Ingelheim has grown its neuroscience research portfolio to incorporate mental health in combination with neurodegenerative disease. This initiative was made deliberately to take advantage of shifts in thinking, such as RDoC. In that time, Boehringer Ingelheim has developed a portfolio of programs that aim to be iteratively more “precise.” This symposium will highlight examples of how Boehringer Ingelheim has shifted its thinking about drug discovery in the mental health space, focusing on the patient rather than the model, and to share some of its successes and failures.
The program will include a presentation at 1 p.m. by Hugh Marston, head of Global CNS Diseases for Boehringer Ingelheim, who will speak on "Using Precision to Bring Innovation to Mental Health Therapeutic Development."
At 2 p.m., Florian Montel, head of Open Science for Boehringer Ingelheim, will give a presentation titled "opnMe.com - How Boehringer Ingelheim Is Fostering Academic Innovation Using Open Innovation."
Networking will follow from 2:30 to 3 p.m.
Lunch will be provided for registered attendees. To register, go to https://cglink.me/2dA/r2272075. For questions or help with registration, please contact Ben Stang at ben.stang@yale.edu.